Literature DB >> 15494657

[Management of malignant epithelial tumors of the ovary].

C Pomel1, J Dauplat.   

Abstract

The notoriously poor prognosis of ovarian cancer requires optimal management by a multidisciplinary gynecologic and oncologic surgical team. Ovarian cancers which appear to be of early stage must be accurately staged to be sure that no potential metastatic sites are missed. Such an omission may have grave consequences for disease progression and may reduce the chances of cure in young patients. With advanced-stage ovarian carcinoma, the challenge is to perform a detailed pre-operative staging of the extent of disease to enable neo-adjuvant chemotherapy when the disease is judged to be inoperable and/or the the general condition of the patient is unsuitable for surgery. Only patients who have had complete cytoreductive surgery to all affected areas in the abdomen can hope to have an acceptable 5 year survival rate of 50%.

Entities:  

Mesh:

Year:  2004        PMID: 15494657     DOI: 10.1016/s0021-7697(04)95334-3

Source DB:  PubMed          Journal:  J Chir (Paris)        ISSN: 0021-7697


  5 in total

Review 1.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Shaun Hiu; Andrew Bryant; Ketankumar Gajjar; Patience T Kunonga; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-08-30

2.  Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network.

Authors:  Hélène Bonsang-Kitzis; Nabilah Panchbhaya; Anne-Sophie Bats; Eric Pujade-Lauraine; Patricia Pautier; Charlotte Ngô; Marie-Aude Le Frère-Belda; Elsa Kalbacher; Anne Floquet; Dominique Berton-Rigaud; Claudia Lefeuvre-Plesse; Michel Fabbro; Isabelle Ray-Coquard; Fabrice Lécuru
Journal:  Cancers (Basel)       Date:  2022-05-09       Impact factor: 6.575

Review 3.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Christine Ang; Karen K L Chan; Andrew Bryant; Raj Naik; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 4.  Cytoreductive surgery in ovarian cancer.

Authors:  Christophe Pomel; Arjun Jeyarajah; David Oram; John Shepherd; David Milliken; Jacques Dauplat; Karina Reynolds
Journal:  Cancer Imaging       Date:  2007-12-17       Impact factor: 3.909

5.  Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival.

Authors:  Yohann Dabi; Cyrille Huchon; Lobna Ouldamer; Sofiane Bendifallah; Pierre Collinet; Alexandre Bricou; Emile Daraï; Marcos Ballester; Vincent Lavoue; Bassam Haddad; Cyril Touboul
Journal:  J Transl Med       Date:  2020-03-23       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.